Ji Wan-Sheng, Gao Zhi-Xing, Wu Kai-Chun, Qiu Jun-Wen, Shi Bing-Long, Fan Dai-Ming
Department of Internal Medicine, Weifang Medical College, Weifang 261042, Shandong Province, China.
World J Gastroenterol. 2005 Feb 21;11(7):986-9. doi: 10.3748/wjg.v11.i7.986.
To demonstrate the effect of Hewei-Decoction (Decoction for regulating the stomach) on chronic atrophic gastritis (CAG) and eradication of Helicobacter pylori.
Ninety patients with CAG entering the investigation were divided into six differentiation syndromes, based on their major symptoms and signs. Hewei-Decoction was taken by all the patients orally for 4 or 8 wk. The efficacy was assessed by both the composite accumulation of reduced scores of major symptoms and the eradication of H pylori. chi(2) test was used to compare the efficacy between H pylori-positive and negative cases, and to disclose the relationship between efficacy and eradication of H pylori.
In patients with six different syndrome types, the efficacy of Hewei-Decoction was 91.67% (11/12), 92.86% (13/14), 97.22% (35/36), 87.50% (14/16), 75.00% (6/8), 75.00% (3/4) respectively. The rate of highly efficacious was 58.33% (7/12), 50.00% (7/14), 77.78% (28/36), 62.50% (10/16), 12.50% (1/8) and 25.00% (1/4), respectively. The total efficacy was 91.11% (82/90), and the rate of highly efficacious was 60.00% (54/90). The eradication rate of H pylori was 67.86% (38/56). The therapeutic effect of Hewei-Decoction was better in H pylori positive cases than that in H pylori-negative cases with the total effect of 96.43% vs 82.35% (P<0.05). In 56 H pylori positive cases, the therapeutic effect was better in H pylori eradicated cases than that in H pylori- existent cases with the total effect of 97.37% vs 72.22% (P<0.01).
Hewei-Decoction is effective in most cases of all the syndrome types. The results indicate that eradication of H pylori is one of the important mechanisms for alleviation of symptoms and signs. Also, the decoction is efficacious in H pylori-negative cases.
观察和胃汤治疗慢性萎缩性胃炎(CAG)及根除幽门螺杆菌的效果。
将90例纳入研究的CAG患者按主要症状和体征分为六个证型。所有患者口服和胃汤4或8周。通过主要症状积分减少的综合累积情况及幽门螺杆菌的根除情况评估疗效。采用χ²检验比较幽门螺杆菌阳性和阴性病例的疗效,并揭示疗效与幽门螺杆菌根除之间的关系。
六个不同证型患者中,和胃汤的有效率分别为91.67%(11/12)、92.86%(13/14)、97.22%(35/36)、87.50%(14/16)、75.00%(6/8)、75.00%(3/4)。显效率分别为58.33%(7/12)、50.00%(7/14)、77.78%(28/36)、62.50%(10/16)、12.50%(1/8)、25.00%(1/4)。总有效率为91.11%(82/90),显效率为60.00%(54/90)。幽门螺杆菌根除率为67.86%(38/56)。和胃汤对幽门螺杆菌阳性病例的治疗效果优于幽门螺杆菌阴性病例,总有效率分别为96.43%和82.35%(P<0.05)。在56例幽门螺杆菌阳性病例中,幽门螺杆菌根除病例的治疗效果优于幽门螺杆菌未根除病例,总有效率分别为97.37%和72.22%(P<0.01)。
和胃汤对各证型的大多数病例有效。结果表明,根除幽门螺杆菌是缓解症状体征的重要机制之一。此外,该方对幽门螺杆菌阴性病例也有效。